BrainTransporter™ dramatically improves antibody delivery to the brain
Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16[th] annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, enabling up to 70-fold higher penetration of antibodies over the blood brain barrier, without negative effects on hematological safety parameters.During the 16[th] annual Protein & Antibody Engineering Summit (PEGS) Europe conference, Dr. Per-Ola Freskgård, VP